Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling. [More]
Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases. [More]
Interventional treatments provide good functional outcomes for patients with lower-grade brain AVMs

Interventional treatments provide good functional outcomes for patients with lower-grade brain AVMs

Interventional treatments--especially surgery--provide good functional outcomes and a high cure rate for patients with lower-grade arteriovenous malformations (AVMs) of the brain, reports the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S. [More]
Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy. [More]
New Tel Aviv University study may pave way for personalized bipolar disorder treatment

New Tel Aviv University study may pave way for personalized bipolar disorder treatment

Rapidly swinging from extremes of joy and energy to sadness, fatigue, and confusion, bipolar disorder (BD) patients feel desperate and largely alone in the world. And according to the National Institutes of Health, between 25-50 percent of the roughly 3% of Americans living with BD attempt suicide at least once. [More]
Ebola survivors face long-term adverse health effects: Study

Ebola survivors face long-term adverse health effects: Study

Ebola survivors experienced negative health effects that persisted more than two years after the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda that claimed 39 lives. These findings are detailed in a paper published online today in Lancet ID. [More]
Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis. [More]
Study finds increasing size of elderly population as major contributor to TB infection in China

Study finds increasing size of elderly population as major contributor to TB infection in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
World Veterans Federation supports approved technology for tinnitus relief among veterans

World Veterans Federation supports approved technology for tinnitus relief among veterans

TINNITUS, a debilitating "ringing in the ears", has become the No. 1 service- connected disability among veterans, surpassing post-traumatic stress disorder. [More]
New treatment shows promise in easing symptoms of Parkinson's disease

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise. [More]
Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday). [More]
BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. [More]
Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Researchers from Montefiore Health System and Albert Einstein College of Medicine will present new findings on how to effectively treat migraine, and forecast the onset of pain in a number of neurological conditions including dementia in older adults. [More]
New clinical utility data for Guardant360 platform to be presented at 2015 AACR Annual Meeting

New clinical utility data for Guardant360 platform to be presented at 2015 AACR Annual Meeting

Guardant Health today announced new clinical utility data for its Guardant360 platform, which will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. [More]
New combination therapy could overcome treatment resistance, relapse in breast cancer

New combination therapy could overcome treatment resistance, relapse in breast cancer

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer. [More]
Advertisement
Advertisement